Anastasia Wyce Selected Research

molibresib

1/2022	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
4/2020	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
1/2020	Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
4/2018	MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
12/2013	Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anastasia Wyce Research Topics

Disease

7	Neoplasms (Cancer) 01/2022 - 01/2008
2	Nausea 01/2022 - 04/2020
2	Carcinoma (Carcinomatosis) 01/2022 - 04/2020
2	Thrombocytopenia (Thrombopenia) 01/2022 - 04/2020
2	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 12/2013
2	Neuroblastoma 01/2020 - 01/2013
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Triple Negative Breast Neoplasms 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Fatigue 04/2020
1	Anemia 04/2020
1	Vomiting 04/2020
1	Diarrhea 04/2020
1	Dysgeusia (Parageusia) 04/2020
1	Carcinogenesis 01/2013
1	Sarcopenia 08/2010
1	Muscular Diseases (Myopathy) 08/2010
1	Neoplasm Metastasis (Metastasis) 01/2008

Drug/Important Bio-Agent (IBA)

5	molibresibIBA 01/2022 - 12/2013
3	Proteins (Proteins, Gene)FDA Link 12/2013 - 01/2008
2	Nuclear Proteins (Protein, Nuclear)IBA 01/2022 - 04/2020
2	4- (1- acetyl- 4- ((4- chlorophenyl)amino)- 2- methyl- 1,2,3,4- tetrahydroquinolin- 6- yl)benzoic acidIBA 01/2020 - 01/2013
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 04/2018
1	Estrogen ReceptorsIBA 01/2022
1	Co-Repressor ProteinsIBA 01/2021
1	MitogensIBA 01/2020
1	Mitogen-Activated Protein KinasesIBA 01/2020
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2020
1	trametinibIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 04/2018
1	AndrogensIBA 08/2010

Therapy/Procedure

4	Therapeutics 01/2020 - 01/2008
1	Drug Tapering 01/2022
1	Castration 01/2022
1	Oral Administration 01/2013